Myocardial infarction and COVID‑19 in a “non‑COVID” hospital: epidemiology, annual analysis
https://doi.org/10.24884/2072-6716-2021-22-4-34-38
Abstract
Purpose of the work: to assess the prevalence of myocardial infarction and COVID-19 in a «non-COVID» hospital.
Materials and methods: the first part of the work is monitoring data from June 2020 to May 2021, the second part is an analysis of monitoring from August 2017 to May 2021.
Research results. According to the data obtained, the peak of the combination of myocardial infarction with COVID-19 lagged behind the total pool of COVID-19 patients by a month, while there was a decrease in the overall incidence of unstable angina pectoris and an increase in the number of patients with myocardial infarction. Obviously, people were slow to seek medical attention. This led to an increase in the time from the onset of symptoms to hospital admission, a later initiation of treatment, and an increase in the incidence of thrombosis in COVID-19 survivors.
Conclusions. In patients, myocardial infarction predominated in the structure of acute coronary syndrome in patients, which is associated, on the one hand, with an increase in the time from the onset of symptoms to admission to the hospital and an increased risk of thrombosis in persons who have undergone COVID-19.
About the Authors
E. G. Skorodumova
St. Petersburg Dzhanelidze Research Institute of Emergency Medicine
Russian Federation
Russian Federation
Elizaveta G. Skorodumova
St. Petersburg
V. A. Kostenko
St. Petersburg Dzhanelidze Research Institute of Emergency Medicine
Russian Federation
Russian Federation
Viktor A. Kostenko
St. Petersburg
E. A. Skorodumova
St. Petersburg Dzhanelidze Research Institute of Emergency Medicine
Russian Federation
Russian Federation
Elena А. Skorodumova
St. Petersburg
A. V. Siverina
St. Petersburg Dzhanelidze Research Institute of Emergency Medicine
Russian Federation
Russian Federation
Anna V. Siverina
St. Petersburg
References
1. Mareev V. Yu., Orlova Ya.A., Plisyuk A. G. Results of an open prospective controlled comparative study on the treatment of novel coronavirus infection (COVID‑19): Bromhexine and Spironolactone for the treatment of Corona Viral Infection Requiring Hospitalization (BISKVIT). Cardiology, 2020, Vol. 60, No. 11, рр. 4–15 (In Russ.)
2. Skorodumova E. G., Kostenko V. A., Skorodumova E. A. et al. Gender differences in the clinical course and prediction of complications of left ventricular myocardial infarction in the practice of the doctor of the first contact. Emergency medical care, 2019, Vol. 20, No. 2, рр. 61–66 (In Russ.)
3. Zabozlaev F. G., Kravchenko E. V., Gallyamova A. R. Pathological anatomy of the lungs with a new coronavirus infection (COVID‑19). Preliminary analysis of autopsy research. Clinical practice, 2020, Vol. 11, No. 2, рр. 60–76 (In Russ.)
4. http://www.yandex.ru/covid19/stat [Электронный ресурс] (дата обращения 06.08.2021).
Review
For citations:
Skorodumova E.G., Kostenko V.A., Skorodumova E.A., Siverina A.V. Myocardial infarction and COVID‑19 in a “non‑COVID” hospital: epidemiology, annual analysis. EMERGENCY MEDICAL CARE. 2021;22(4):34-38. (In Russ.) https://doi.org/10.24884/2072-6716-2021-22-4-34-38
Views:
521
Email this article 